Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Pia Nierman

acalabrutinib, chronic lymphocytic leukemia, adverse events
CJON 2021, 25(6), 687-696. DOI: 10.1188/21.CJON.687-696

Background: Acalabrutinib is a next-generation Bruton tyrosine kinase inhibitor (BTKi) that has moved to the forefront of treatment options for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients with CLL/SLL can experience adverse events and toxicities unique to BTKi therapy.

Objectives: This article provides an overview of nursing considerations for the treatment of patients with CLL/SLL with acalabrutinib, focusing on safety, toxicity management, and adherence.

Methods: A review of information identified through structured searches of key publications and websites and data from pivotal clinical trials was performed.

Findings: Increased awareness of the unique disease characteristics of patients with CLL/SLL and of the efficacy and safety profile of acalabrutinib allows nurses to play a vital role in improving patient outcomes. With this knowledge, nurses can support patients through education on potential side effects, drug–drug interactions, and treatment adherence, as well as monitor for clinical symptoms and laboratory findings requiring intervention.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.